Making the Most of Drug Discovery Data By Dr Nick Davies and Dr Tim Peakman Discovery scientists in most pharmaceutical companies are struggling with incompatible legacy systems, a growing volume of data and the imminent advent of a product model that will demand much more of them. Read More
Gene Expression: Analysis and Drug R&D By Dr Ralph Sinibaldi It is clear that gene expression profiling systems have a role to play in many facets of drug discovery and development, but several questions remain. We take a look at the use of DNA microarray for gene expression… Read More
Using RNAi to identify and validate novel drug targets: targeting human kinases with an siRNA library By Andrea Kroenke, Anne Grabner, Dr Michael Hannus, Dr Christoph Sachse, Dr David Dorris and Dr Christophe Echeverri Libraries of siRNAs directed against predefined subsets of genes now offer the capacity… Read More
Fewer drugs approved, more money spent – Where’s the beef? By G. Steven Burrill Three years ago, when biotech was at its Wall Street heights, personalised medicine and its promise were on everyone’s lips. Billions of dollars were being put to work to make targeted medicine a… Read More
Recent advances in mass spectrometry for drug discovery and development By Dr Nelson Cooke Of the numerous types of analytical techniques used in drug discovery and development, mass spectrometry (MS) has become one of the most powerful tools for the analyses of a wide range of chemical… Read More
By Dr Steven Bodovitz and Dr Scott D. Patterson The potential for parallel protein-based analyses to define a new era in diagnostics and drug development is generating considerable excitement in the field of proteomics. However, the discovery of differentially expressed proteins that correlate with a disease… Read More
Synthetic approaches to rational drug design – A changing landscape By Dr Shubh Sharma and Dr Carl Spana It is becoming clearer that newer synthetic approaches for rational drug design may hold the promise of taking us closer to industrialising drug discovery while, at the same time, overcoming… Read More
The Protein Biochip Content Problem By Dr Steven Bodovitz The protein biochip industry has a content problem that is not only slowing its development as a whole but possibly the development of the entire proteomics industry. In science, for a problem to have… Read More
RNA interference – A technology platform for target validation, drug discovery and therapeutic development By Dr Krishnarao Appasani In the post genomic era, elucidation of the physiological function of genes has become a major rate-limiting step in the quest to develop ‘gene-based-drugs’. As we… Read More
Functional proteomics in drug discovery By Dr Stefan W. Henning and Dr Leodevico L. Ilag The critical bottleneck of the drug discovery process is developing the right drug for the right target. Today proteins represent more than 90% of druggable targets and will most… Read More
Protein Arrays for Assessment of Target Selectivity By Professor Ian Humphery-Smith, Dr Erik Wischerhoff and Dr Ryuji Hashimoto Transforming knowledge of the human genome into a lead optimisation tool. Genomics activity has been criticised for having elucidated a plethora of potentially interesting drug… Read More
Better drugs by MICROARRAY By Dr Mark Schena Microarray analysis allows the elucidation of biological processes and pathways on a genomic scale. This revolutionary technology promises an unprecedented view of drug action and side reaction, the ability to identify drug targets and optimise lead… Read More
The New Blockbuster Drugs – Healthcare packages for particular disease pathologies By Dr Nick Davies and Dr Steve Arlington With the cost of bringing a new drug to market now exceeding $800 million there is no doubt that the pharmaceutical industry has to fundamentally address the way in… Read More
Protein Biochips – On the threshold of success By Dr Steven Bodovitz and Felicia Gentile With sales of protein biochips set to top $700 million in 2006, we present a current overview of this fast moving technology and the applications for the pharmaceutical industry as a whole. Read More
The emergence of pharmacogenomics within the pharmaceutical industry By Aidan Power, Suzin Webb, Dr Albert Seymour and Dr Patrice Milos The sequencing of the human genome represents one of the most significant scientific advances of the 20th century that will shape the foundation of medical research well… Read More
The Once and Future Microarray Market By Dr Ken Rubenstein Although the future for micorarray technology looks bright, the DNA microarray consumer is faced with a number of important choices regarding sources and technologies. Developers, users, and afficionados of DNA microarray technology, who… Read More
